View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 13, 2021updated 11 Jul 2022 2:22pm

Arcturus obtains approval for Phase IIIb Covid vaccine trial in Vietnam

The trial will have nearly 20,000 subjects, who will receive two doses of the vaccine 28 days apart or a placebo. 

The Vietnam Ministry of Health has granted approval to Arcturus Therapeutics for commencing the Phase IIIb portion of Phase I/II/III clinical trial assessing its Covid-19 vaccine, ARCT-154, against SARS-CoV-2 delta variant and other variants of concern.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The company has started dosing the subjects in the trial, which will enrol nearly 20,000 subjects.

They will be given either two doses of the vaccine administered at a gap of 28 days or a placebo.

The approval to progress to Phase IIIb trial comes after a review of positive safety data obtained from the initial 1,000 subjects who were part of the placebo-controlled, observer-blind Phase I/II/IIIa trial.

To date, the Phase I segment has concluded the priming vaccination series with two doses in 100 people, with 75 subjects being enrolled in the ARCT-154 group.

The Phase II and Phase IIa portions are underway, enrolling 300 and 600 subjects, respectively.

Arcturus Therapeutics president and CEO Joseph Payne said: “Initiation of dosing in the Phase IIIb portion of the study brings us one step closer to our goal of filing for EUA and making it available as quickly as possible.

“As a low dose vaccine targeting variants of concern, ARCT-154 has a differentiated profile compared to currently available vaccines and we believe that our programme has the potential to become a best-in-class option for Vietnam and many other countries around the world.”

The company, along with its manufacturing partner, Vinbiocare Biotechnology , plans to seek emergency use authorization (EUA) for the vaccine in Vietnam in December this year.

This August, Arcturus reported that Vinbiocare received approval from the Vietnam Ministry of Health to conduct Phase I/II/III trial of ARCT-154.

During the same month, Arcturus and Vinbiocare signed a collaboration agreement to build a manufacturing plant in Vietnam to produce the former’s experimental Covid-19 vaccines for supply and use in the country.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena